GlassScriptPhysician profile
Rachel Kaplan
NPI 1699088997
$2,063.78
in general payments reported to CMS, 2019-2025
29 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $56.99 · 2021: $318 · 2022: $424 · 2023: $287 · 2024: $540 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.08 | 2019-2024 | |
| Astellas Pharma US INC | $258.00 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $171.23 | 2021-2025 | |
| Hologic Sales and Service, LLC | $150.34 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $139.22 | 2020-2025 | |
| Therapeuticsmd, INC. | $110.85 | 2019-2022 | |
| Exeltis, USA INC. | $105.61 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $97.85 | 2019-2025 | Paragard T 380a, Summit Doppler |
| Organon LLC | $69.03 | 2022-2024 | |
| Sage Therapeutics, LLC | $61.24 | 2024 | |
| Heron Therapeutics, INC. | $60.28 | 2022-2023 | Zynrelef |
| Daiichi Sankyo INC. | $50.20 | 2019-2024 | Injectafer |
| Minerva Surgical, INC | $42.46 | 2019-2025 | |
| Pfizer INC. | $36.53 | 2022 | |
| Optumhealth Care Solutions, LLC | $34.19 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $30.26 | 2022 | |
| Agile Therapeutics, INC. | $25.77 | 2022-2024 | Twirla |
| Coloplast Corp | $24.30 | 2022 | |
| Lupin INC. | $23.75 | 2019 | |
| Shield Therapeutics INC | $19.46 | 2024 | |
| Evofem Biosciences, INC. | $19.33 | 2020 | |
| Myovant Sciences INC. | $18.53 | 2022 | |
| Sumitomo Pharma America, INC. | $17.16 | 2024 | Myfembree |
| Novo Nordisk INC | $15.74 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $14.46 | 2021 | |
| Avion Pharmaceuticals | $12.76 | 2022 | |
| Virtus Pharmaceuticals LLC | $12.15 | 2021 | |
| Allergan, INC. | $11.56 | 2019 | |
| Meditrina | $7.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.